BlissM: The history of insulin. Diabetes Care, 1993; 16Suppl 3:4–7.
2.
QuianzonCC, CheikhI: History of insulin. J Community Hosp Intern Med Perspect, 2012; 2. http://dx.doi.org/10.3402/jchimp.v2i2.18701.
3.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329:977–986.
4.
Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care, 2016; 39:686–693.
5.
HirschIB: Insulin analogues. N Engl J Med, 2005; 352:174–183.
6.
RiddleMC, RosenstockJ, GerichJ; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003; 26:3080–3086.
7.
FDA approves first automated insulin delivery device for type 1 diabetes. FDA, 2016. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522974.htm (accessed January5, 2017).
8.
PetersAL, PollomRD, ZielonkaJS, et al.: Biosimilars and new insulin versions. Endocr Pract, 2015; 21:1387–1394.
9.
LucioSD, StevensonJG, HoffmanJM: Biosimilars: implications for health-system pharmacists. Am J Health Syst Pharm, 2013; 70:2004–2017.
10.
HeinemannL, FritzI, KhatamiH, EdelmanSV: Administration of biosimilar insulin analogs: role of devices. Diabetes Technol Ther, 2017; 19:79–84.
11.
BlevinsTC, DahlD, RosenstockJ, et al.: Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab, 2015; 17:726–733.
12.
HadjiyianniI, DahlD, LacayaLB, et al.: Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Diabetes Obes Metab, 2016; 18:425–429.
13.
IlagLL, DeegMA, CostiganT, et al.: Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obes Metab, 2016; 18:159–168.
14.
LinnebjergH, LamEC, SegerME, et al.: Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care, 2015; 38:2226–2233.
15.
RosenstockJ, HollanderP, BhargavaA, et al.: Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab, 2015; 17:734–741.
16.
FriedrichsA, BohnetJ, KorgerV, et al.: Dose accuracy and injection force of different insulin glargine pens. J Diabetes Sci Technol, 2013; 7:1346–1353.
17.
BohnetJ, SchmitzM, KamlotS, Abdel-TawabM: Dosing accuracy and insulin flow rate characteristics of a new disposable insulin pen, FlexTouch, compared with SoloSTAR. J Diabetes Sci Technol, 2013; 7:1021–1026.
18.
LasalviaP, Barahona-CorreaJE, Romero-AlverniaDM, et al.: Pen devices for insulin self-administration compared with needle and vial: systematic review of the literature and meta-analysis. J Diabetes Sci Technol, 2016; 10:959–966.
19.
IgnautDA, SchwartzSL, SarwatS, MurphyHL: Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ, 2009; 35:789–798.
20.
RidyardCH, DawoudDM, TuersleyLV, HughesDA: A systematic review of patients' perspectives on the subcutaneous route of medication administration. Patient, 2016; 9:281–292.
21.
RamadanWH, KhreisNA, KabbaraWK: Simplicity, safety, and acceptability of insulin pen use versus the conventional vial/syringe device in patients with type 1 and type 2 diabetes mellitus in Lebanon. Patient Prefer Adherence, 2015; 9:517–528.
22.
SeggelkeSA, HawkinsRM, GibbsJ, et al.: Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes. Endocr Pract, 2014; 20:536–539.
23.
AhmannA, SzeinbachSL, GillJ, et al.: Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes. Diabetes Technol Ther, 2014; 16:76–83.
24.
PfutznerA, BaileyT, CamposC, et al.: Accuracy and preference assessment of prefilled insulin pen versus vial and syringe with diabetes patients, caregivers, and healthcare professionals. Curr Med Res Opin, 2013; 29:475–481.
25.
LajaraR, GuerreroG, ThurmanJ: Healthcare professional and patient perceptions of a new prefilled insulin pen versus vial and syringe. Expert Opin Drug Deliv, 2012; 9:1181–1196.
26.
CamposC, LajaraR, DeluzioT: Usability and preference assessment of a new prefilled insulin pen versus vial and syringe in people with diabetes, physicians and nurses. Expert Opin Pharmacother, 2012; 13:1837–1846.
27.
MolifeC, LeeLJ, ShiL, et al.: Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther, 2009; 11:529–538.
28.
KorytkowskiM, BellD, JacobsenC, SuwannasariR; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther, 2003; 25:2836–2848.
29.
HeinemannL: Biosimilar insulin and costs: what can we expect?. J Diabetes Sci Technol, 2015; 10:457–462.
30.
WilkinsAR, VenkatMV, BrownAS, et al.: Patient perspectives on biosimilar insulin. J Diabetes Sci Technol, 2014; 8:23–25.
31.
GreeneJA, RiggsKR: Why is there no generic insulin? Historical origins of a modern problem. N Engl J Med, 2015; 372:1171–1175.
32.
TsaiA: The Rising Cost of Insulin. Diabetes Forecast: American Diabetes Association, Arlington, VA; 2016.
